



April 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2014-001639-35/ Novartis Protocol ID CRFB002DDE25

A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis

Trial CRFB002DDE25 was cancelled with no patient enrollment and as such, no results will be reported.